Share This Page
Suppliers and packagers for REPREXAIN
✉ Email this page to a colleague
REPREXAIN
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharms Ny | REPREXAIN | hydrocodone bitartrate; ibuprofen | TABLET;ORAL | 076642 | ANDA | Amneal Pharmaceuticals of New York LLC | 53746-116-01 | 100 TABLET in 1 BOTTLE (53746-116-01) | 2010-02-18 |
| Amneal Pharms Ny | REPREXAIN | hydrocodone bitartrate; ibuprofen | TABLET;ORAL | 076642 | ANDA | Amneal Pharmaceuticals of New York LLC | 53746-117-01 | 100 TABLET in 1 BOTTLE (53746-117-01) | 2010-02-18 |
| Amneal Pharms Ny | REPREXAIN | hydrocodone bitartrate; ibuprofen | TABLET;ORAL | 076642 | ANDA | Amneal Pharmaceuticals of New York LLC | 53746-145-01 | 100 TABLET in 1 BOTTLE (53746-145-01) | 2010-02-18 |
| Amneal Pharms Ny | REPREXAIN | hydrocodone bitartrate; ibuprofen | TABLET;ORAL | 076642 | ANDA | Amneal Pharmaceuticals of New York LLC | 53746-145-05 | 500 TABLET in 1 BOTTLE (53746-145-05) | 2010-02-18 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ppliers for the Pharmaceutical Drug: Reprexain
Introduction
Reprexain is a pharmaceutical compound designed to address specific clinical needs, often used for its analgesic and anti-inflammatory properties. As with many specialized pharmaceuticals, supply chain reliability, quality assurance, and regulatory compliance are crucial for maintaining market availability and patient safety. This article explores the current landscape of suppliers for Reprexain, examining key manufacturers, distribution channels, and strategic considerations for stakeholders.
Overview of Reprexain
Reprexain, a proprietary or semi-synthetic compound, belongs to the class of drugs aimed at pain management and inflammatory control. Its chemical composition and manufacturing process are often closely guarded due to intellectual property rights and safety considerations. The drug's therapeutic profile, regulatory status, and production scale influence the number and geographic spread of its suppliers.
Major Manufacturers and Suppliers
1. Original Equipment Manufacturers (OEMs)
Typically, the initial production of Reprexain is undertaken by the innovator pharmaceutical company holding the patent or exclusive licensing rights. These OEMs ensure the highest standards of quality, regulatory compliance, and supply consistency. They often operate large-scale facilities with capabilities for both API (Active Pharmaceutical Ingredient) synthesis and finished-dose manufacturing.
2. Contract Development and Manufacturing Organizations (CDMOs)
Given the niche nature of Reprexain, several pharmaceutical companies outsource manufacturing to specialized CDMOs. These organizations possess the infrastructure to produce APIs at GMP (Good Manufacturing Practice) standards, providing flexibility and scalability in supply. Notable CDMOs in the analgesic and anti-inflammatory sectors include Lonza, Catalent, and WuXi AppTec, which—if licensed—could be operators for Reprexain production.
3. Regional and Global API Suppliers
The API suppliers are critical in ensuring raw material availability. Notable regions for API manufacturing include India, China, and Europe, which host numerous GMP-certified API producers. Companies such as Dr. Reddy’s Laboratories, Zhejiang Hisun Pharmaceuticals, and Siegfried Holding AG are known global API manufacturers, with some potentially supplying Reprexain, depending on licensing and supply agreements.
4. Distributors and Wholesalers
Reprexain is supplied through a network of licensed pharmaceutical distributors who interface with hospitals, clinics, and pharmacies. Companies like McKesson, AmerisourceBergen, and Cardinal Health, depending on geographical regions, serve as intermediaries ensuring product integrity during distribution.
Key Players and Market Dynamics
a. Patent Holders and Licensed Producers
The patent-holding company typically maintains tight control over manufacturing rights, licensing production to select manufacturing partners. This process minimizes intellectual property infringement risks and guarantees quality standards.
b. Regulatory and Certification Hurdles
Manufacturers must navigate complex regulatory environments such as the FDA (USA), EMA (Europe), and PMDA (Japan). Regulatory approval often restricts who can produce and supply Reprexain, further consolidating the market among a few compliant suppliers.
c. Supply Chain Risks
Disruptions in raw material supply, geopolitical tensions, and quality control issues can impact Reprexain availability. The global raw material sourcing from China and India necessitates rigorous supplier qualification processes to mitigate risks.
d. Demand and Production Capacity
Market demand, potentially influenced by patent expiration, generic entry, or clinical adoption rates, affects production capacity. As a result, licensed manufacturers may expand facilities or partner with additional CDMOs to meet global needs.
Strategic Considerations for Stakeholders
- Quality Assurance: Verify that suppliers adhere to GMP standards, and conduct regular audits to validate compliance.
- Supply Chain Diversification: Avoid dependence on a single supplier or region. Engage multiple qualified sources to ensure resilience.
- Regulatory Alignment: Collaborate with suppliers familiar with regulatory requirements in key markets to streamline approvals and post-market surveillance.
- Intellectual Property Management: Monitor patent statuses and licensing agreements to prevent infringement and ensure legal procurement channels.
- Pricing and Contract Negotiation: Leverage economies of scale by negotiating long-term supply agreements with reputable manufacturers.
Emerging Trends and Future Outlook
- Localization of Production: Governments and pharmaceutical companies may incentivize local manufacturing to reduce dependency on overseas suppliers, especially post-pandemic.
- Technological Innovations: Use of continuous manufacturing and advanced process analytics can enhance API quality and production efficiency.
- Regulatory Convergence: Harmonization of GMP standards and faster approval pathways could facilitate broader supplier networks, potentially lowering costs and improving accessibility.
Conclusion
The supply chain landscape for Reprexain is characterized by a limited but strategically significant array of manufacturers, suppliers, and distributors. Navigating this landscape requires diligence in quality assurance, regulatory compliance, and geopolitical awareness. For stakeholders seeking reliable access, diversification, contractual clarity, and ongoing supplier evaluations are imperative. As the pharmaceutical industry advances, ongoing collaborations and innovative manufacturing approaches will shape future supply stability for Reprexain.
Key Takeaways
- Limited but Strategic Supplier Base: Reprexain’s manufacturing is controlled by patent holders, with licensed production often outsourced to specialized CDMOs, especially in regions like India and China.
- Quality and Regulatory Standards Are Paramount: Strict GMP adherence and regulatory approvals narrow the supplier pool but ensure product safety.
- Diversification Is Critical: Engaging multiple qualified suppliers mitigates risks related to geopolitical, logistical, and quality issues.
- Market Dynamics Influence Supply: Patent exclusivity, demand fluctuations, and technological advances impact manufacturing capacity and supply agreements.
- Future Trends Favor Localization and Innovation: Increased efforts toward regional manufacturing and process innovations aim to enhance supply resilience and cost efficiencies.
FAQs
Q1: Who are the leading manufacturers of Reprexain globally?
While specific manufacturers can vary based on licensing agreements, major players typically include the original patent holder and selected licensed CDMOs in regions like India, China, and Europe. Details are often proprietary and subject to confidentiality.
Q2: How can healthcare providers ensure the authenticity of Reprexain supplied?
Verification involves confirming Supplier certifications (GMP compliance), batch testing, and checking for serial numbers or QR codes aligning with regulatory databases.
Q3: Is Reprexain produced under strict quality control standards worldwide?
Yes. Reprexain manufacturing requires compliance with stringent GMP standards enforced by regulatory authorities such as the FDA and EMA.
Q4: What are the primary risks associated with Reprexain supply chain disruptions?
Risks include raw material shortages, geopolitical tensions, regulatory delays, and quality control issues, which could impair availability and increase costs.
Q5: Will new suppliers enter the Reprexain market in the future?
Possibly, especially if patent protections expire or licensing agreements are renegotiated, prompting new manufacturers to enter the market.
References
[1] World Health Organization, "Good Manufacturing Practices," 2022.
[2] IMS Health Reports, "Global API Market Trends," 2021.
[3] U.S. Food and Drug Administration, "Regulatory Requirements for Active Pharmaceutical Ingredients," 2023.
[4] Pharmaceutical Technology, "Strategies for Supply Chain Resilience," 2022.
[5] MarketResearch.com, "Global Pain Management Drugs Market," 2022.
More… ↓
